BioNTech (BNTX) Stock Price, News & Analysis

Company Overview

BioNTech SE is a global biotechnology company headquartered in Mainz, Germany, focused on developing and commercializing novel immunotherapies for the treatment of cancer and infectious diseases. Established in 2008 by scientists Uğur Şahin, Özlem Türeci and Christoph Huber, the company has pioneered the use of messenger RNA (mRNA) technology to instruct the body’s own cells to produce disease-fighting proteins. BioNTech’s integrated development platform spans mRNA therapeutics, individualized cellular therapies, antibody-based approaches and innovative protein subunit technologies.

At the core of BioNTech’s business is its mRNA platform, which supports a broad pipeline of vaccine and therapeutic candidates. The company’s oncology portfolio includes individualized neoantigen therapies, CAR-T cell programs and bispecific antibodies aimed at mobilizing the immune system against solid tumors and hematological malignancies. In parallel, BioNTech has advanced mRNA-based vaccines for infectious diseases, most notably through its collaboration with Pfizer to develop the COVID-19 vaccine, which validated the speed and scalability of its manufacturing processes.

Since its initial public offering on the NASDAQ in 2019, BioNTech has expanded its global footprint and invested heavily in research and manufacturing capacity. The company operates production facilities in Europe and the United States, while partnering with regional distributors in Asia and Latin America to accelerate access to its products. BioNTech’s strategic alliances extend to pharmaceutical partners such as Pfizer, Fosun Pharma and Genentech, enabling co-development and commercialization of therapies across multiple indications.

Under the leadership of Chief Executive Officer Uğur Şahin and Chief Medical Officer Özlem Türeci, BioNTech maintains a science-driven culture with a focus on precision medicine. The executive management team and scientific advisory board bring deep expertise in immunology, oncology, vaccinology and regulatory affairs. Looking ahead, BioNTech aims to leverage its proprietary platforms to address unmet medical needs and deliver personalized treatments on a global scale.

Key Stats

• Today's Range: $108.05 to $111.82
• 50-Day Range: $92.08 to $115.64
• 52-Week Range: $76.53 to $131.49
• Volume: 613,718 shs
• Average Volume: 944,276 shs
• Market Capitalization: $26.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $137.86
• Consensus Rating: Moderate Buy

BioNTech Stock Analysis - MarketRank™

BioNTech scored higher than 47% of companies evaluated by MarketBeat, and ranked 571st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BioNTech are expected to decrease in the coming year, from ($3.88) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioNTech is -32.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioNTech is -32.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioNTech has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.58% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in BioNTech has recently increased by 17.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioNTech does not currently pay a dividend.

Dividend Growth

BioNTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.58% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in BioNTech has recently increased by 17.50%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.06

News Sentiment

BioNTech has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for BioNTech this week, compared to 12 articles on an average week.

Search Interest

Only 25 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioNTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.52% of the stock of BioNTech is held by institutions.

BNTX Stock Analysis - Frequently Asked Questions

How have BNTX shares performed this year?

BioNTech's stock was trading at $113.95 on January 1st, 2025. Since then, BNTX shares have decreased by 3.8% and is now trading at $109.6450.

How were BioNTech's earnings last quarter?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) announced its quarterly earnings data on Monday, March, 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The business's revenue for the quarter was down 19.5% on a year-over-year basis.
Read the conference call transcript.

Does BioNTech have any subsidiaries?

BioNTech subsidiaries include Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more.

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 3/10/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTX
• CIK: 1776985
• Web: www.biontech.de
• Phone: 49-61-31908-40
• Fax: 49-6131-908-4390
• Employees: 6,772
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $137.86
• High Stock Price Target: $171.44
• Low Stock Price Target: $110.00
• Potential Upside/Downside: +25.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$719.92 million
• Net Margins: -27.37%
• Pretax Margin: -28.38%
• Return on Equity: -3.94%
• Return on Assets: -3.41%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 10.18
• Quick Ratio: 10.02

Sales & Book Value

• Annual Sales: $2.98 billion
• Price / Sales: 8.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $87.61 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 240,390,000
• Free Float: 194,238,000
• Market Cap: $26.36 billion
• Optionable: Optionable
• Beta: 1.29